RNA interference

Ask MedXY AI

Latest news

Tag

CardiologyATTR-CMheart failure

Vutrisiran Redefines the Therapeutic Landscape for Transthyretin Amyloidosis with Cardiomyopathy: Comprehensive Insights from the HELIOS-B Trial

By MedXY|Dec 25, 2025

The HELIOS-B trial demonstrates that vutrisiran significantly improves clinical outcomes, stabilizes cardiac biomarkers, preserves cardiac structure, and enhances the quality of life in patients with transthyretin amyloidosis with cardiomyo

Clinical UpdatesHSD17B13metabolic dysfunction-associated steatohepatitis

Rapirosiran: A Promising RNAi Therapy Targeting HSD17B13 in Metabolic Dysfunction-Associated Steatohepatitis

By MedXY|Oct 8, 2025

This phase I study evaluates rapirosiran, an RNA interference therapeutic targeting HSD17B13, demonstrating safety, tolerability, and significant liver mRNA reduction in patients with metabolic dysfunction-associated steatohepatitis (MASH).